Every year, thousands of Canadian children are diagnosed with, or treated for, brain disorders such as Fetal Alcohol Spectrum Disorders (FASD), Autism Spectrum Disorders (ASD) and cerebral palsy. As a national scientific research network, NeuroDevNet has dedicated its mission towards finding the root causes of these disorders.
Through a Mitacs Accelerate internship at the end of her Masters at Simon Fraser University, Vivien Lo was asked to develop a cost-benefit model for their technology— a challenge which landed her a job with the company full-time.
Having already completed Bachelor’s and Master’s degrees in Cellular Biology, Vivien found herself craving an entry into industry. This led her to SFU’s 2-year Masters of Business Administration for the Management of Technology (MBAMOT) program where she was awarded a Mitacs Accelerate internship for a graduating final project in the fall of 2011.
After completing his Bachelors and Masters degrees in Tehran, then working at a car manufacturing company, the loss of a close family member to cancer changed his goals for the future. He set his sights on biotechnology at the University of British Columbia. Ahmadi initially thought this meant a career destined for academia, but since attending eight Mitacs Step workshops he says “My eyes were opened to the opportunities outside of academia and I started to think about my career differently.”
This September, Nivarti is returning to the University of British Columbia to start his master's degree, after graduating from the Indian Institute of Technology Kharagpur with the best mark in his class for his honours thesis in mechanical engineering.
Nivarti chose UBC over schools like MIT and Stanford because of his Globalink experience, which paired the mechanical engineering student with Kendal Bushe, a UBC assistant professor who is one of North America's most highly respected combustion researchers. Dr. Bushe will also supervise Nivarti's graduate work.
Over the course of his Accelerate internship Zaifman, a postdoctoral fellow at the Chemistry department of the University of British Columbia, partnered with AlCana, a Vancouver biotechnology company developing lipid nanoparticles, which show great potential as a new means for the targeted delivery of therapeutics.